Drug Trial Radar · NCT02922166
Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans
Last checked: Nov 19, 2026Latest source record: Jun 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
36
Actual
Start
Feb 3, 2017
Primary completion
May 10, 2019
Study completion Dec 2019
Sponsor
- Lead sponsor
- Azevan PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute of Mental Health (NIMH)
- First posted
- Oct 4, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To determine the effects of SRX246 on fear and anxiety based on fear-potentiated startle in humans. Additionally, the effects of the compound on emotion recognition will be explored.
Conditions
- Fear
- Anxiety
Interventions
SRX246Drug
oral capsule
PlaceboDrug
oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in startle reflex between SRX246 and PlaceboTime frame: up to 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institute of Mental Health
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.